Testing YG-01 for safety and dose in people with glioblastoma
Tests a new drug, YG-01, in adults with glioblastoma, a brain tumor.
Key facts
- Who runs it
- YGION Biomedical GmbH
- Where
- Vienna, AustriaSee the site
- Trial code
- NCT07930338
- EU 2025-524299-44-00
- U1111-1330-5924
- Registry title
- First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 15 people, planned
- Started
- Nov 2026
- Expected to end
- Nov 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- YG-01 Dose Level 1
- YG-01 Dose Level 2
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 35 criteriaShow less
Other criteria
- Pre-Production Screening inclusion criteria:
- Patient provided written informed consent for study participation prior to initiation of any study specific activities/procedures
- Histologically confirmed glioblastoma, IDH wild type, WHO CNS Grade 4 - classification according to WHO classification of CNS tumors 2021; patients of dose escalation cohorts are required to have undergone extensive tumor resection documented by post-surgical magnetic resonance imaging (MRI) demonstrating either no contrast enhancement or no greater than 1 cm x 1 cm x 1 cm volume of residual enhancing tumor
- Age ≥18 years
- ECOG 0-1
- At least 4 manufacturable neoepitopes identified in a preceding tumor sample analysis study and availability of a manufacturing slot confirmed by the sponsor
- Stable disease or no measurable disease according to local investigator assessment, following at least two MRI scans taken a minimum of 8 weeks apart, both conducted after the completion of standard 6 weeks radiotherapy with concurrent temozolomide; Pre-Therapy Screening inclusion criteria:
- Having completed maintenance temozolomide therapy, received at least 4 cycles of temozolomide, and having an interval of at least 4 weeks between the last dose of temozolomide and the first administration of study medication
- Stable disease or no measurable disease according to local investigator assessment, following an MRI scan taken after the completion of maintenance temozolomide therapy
- Life expectancy > 3 months at start of study treatment as clinically determined by the investigator
- ECOG 0-1
- Availability of study medication confirmed by the sponsor
- Absolute lymphocyte count (ALC) >0.75 x10\^9/L
- No need for dexamethasone or any other steroid treatment within 1 week prior to baseline
- No need for bevacizumab treatment within 1 week prior to baseline; Pre-Production Screening exclusion criteria:
- Known HIV or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or known infections that can cause a severe disease and pose a severe danger to lab personnel working on patient's blood or tissue
- Concurrent participation in another interventional clinical trial studying a drug or treatment regimen
- Clinically relevant autoimmune diseases (with the exception of autoimmune thyroid disease) that, in the investigator's judgement, may interfere with study participation
- Immunosuppression, not related to treatment for glioblastoma
- History of severe hypersensitivity reactions
- Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from YG-01 treatment (e.g., high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance issues)
- Clinically relevant illness or condition which may affect the patient's safety during the study or impede the patient's ability to complete the study, as assessed by the investigator
- History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) unless the patient has been disease-free for the last 5 years
- Pregnancy or breastfeeding; Pre-Therapy Screening exclusion criteria:
- Abnormal (≥ grade 2 CTCAE v6.0) laboratory values for hematology, liver and renal function (serum creatinine)
- HIV infection or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or known infections that can cause a severe disease and pose a severe danger to lab personnel working on patient's blood or tissue
- Concurrent participation in another interventional clinical trial studying a drug or treatment regimen
- Clinically relevant autoimmune diseases (with the exception of autoimmune thyroid disease) that, in the investigator's judgement, may interfere with study participation
- Any vaccination within 2 weeks prior to baseline
- Immunosuppression, not related to prior treatment for glioblastoma
- History of severe hypersensitivity reactions
- Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from YG-01 treatment (e.g., high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance issues)
- Clinically relevant illness or condition which may affect the patient's safety during the study or impede the patient's ability to complete the study, as assessed by the investigator
- History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) unless the patient has been disease-free for the last 5 years
- Pregnancy or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old are you?
Where in Austria
- Medical University of ViennaVienna, AustriaTaking people
About the trial
What the trial wants to find out
This is a first-in-human, open-label, single-arm, dose-escalation Phase 1 clinical study evaluating the safety, tolerability, feasibility, and immunogenicity of the YG-01, a personalized neoantigen peptide-based cancer immunotherapy, in patients with diagnosed glioblastoma following standard-of-care therapy. The study will assess the safety and tolerability of repeated administrations of YG-01 and explore immune responses and clinical outcomes following treatment. The study includes sequential dose-escalation cohorts to evaluate the safety and tolerability of increasing dose levels of YG-01 and to identify a recommended dose for further clinical development.
The 2 groups in the trial
- Dose Level 1Treatment being tested
Patients receive YG-01, a personalized neoantigen immunotherapy comprising patient-specific neoepitope peptides administered subcutaneously at Dose Level 1.
Treatment: YG-01 Dose Level 1
- Dose Level 2Treatment being tested
Patients receive YG-01 at Dose Level 2 subcutaneously on the same schedule as Dose Level 1, started after Safety Committee review of Dose Level 1.
Treatment: YG-01 Dose Level 2
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Phase 1 Dose-escalation Study of YG-01 in Patients With Glioblastoma
- Plain-language title
- Testing YG-01 for safety and dose in people with glioblastomaGenerated from the registry record. The registry title is the official one.
- Fit questions
- Built from NCT07930338, who can take part
- Record updated
- 12 November 2026